Keywords: bayer, pay, up, 385m, ex-us, sale, rights

Bayer to pay up to $385M for ex-US sale rights to Nuvelo's Ph III thrombolytic, alfimeprase

Article | 16 January 2006

Germany's Bayer HealthCare has entered into a collaboration agreement with California, USA-based drug discovery firm Nuvelo for the global development ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bayer

Drug Discovery

Aventis

Aventis Pharma

Sanofi-Aventis

Go to company listing

Related Drugs

Bayer

Aspirin

Lovenox

Enoxaparin Sodium Injection

Coagulation Factor VIIa

Go to drug listing